BNT23002: Breakthrough Therapy for Myasthenia Gravis (MG)

Innovative Sublingual Cladribine for Enhanced Patient Care

BNT23002, BioNxt’s sublingual Cladribine film, offers a groundbreaking approach to managing myasthenia gravis (MG). Utilizing our advanced oral dissolvable film (ODF) technology, BNT23002 addresses the unique needs of MG patients, many of whom face challenges with traditional oral medications due to swallowing difficulties. This innovative format provides a patient-friendly, fast-acting solution that simplifies treatment and improves patient experience.

Why BNT23002?

• Enhanced Patient Compliance: MG patients often struggle with traditional oral medications due to swallowing difficulties. BNT23002’s dissolvable film is easy to administer, helping patients adhere to their treatment plan more comfortably.
• Rapid Absorption and Improved Bioavailability: The sublingual delivery bypasses the gastrointestinal tract, offering faster drug onset and better bioavailability of Cladribine. This allows for potentially lower, more effective doses and can reduce side effects.
• Orphan Drug Status Advantage: BNT23002 benefits from orphan drug status, which extends market exclusivity, providing a competitive edge while meeting the specific needs of the MG community.

Addressing a Significant Need in Myasthenia Gravis Treatment

The MG treatment market is projected to double by 2032, reaching $6.7 billion. With approximately 14-40 people per 100,000 affected in the U.S., there is a pressing need for improved therapies that are convenient and effective. BNT23002’s sublingual film is uniquely positioned to meet this need, offering MG patients a safer and easier way to receive their treatment.

Product Features

• Portable & Convenient: Compact and easy to carry, BNT23002 provides flexibility for on-the-go treatment.
• Quick Dissolution: The film dissolves quickly under the tongue, delivering the medication directly to the bloodstream.
• Non-Invasive Solution: Unlike injections, BNT23002 provides a comfortable, non-invasive alternative for patients.
• Proven Therapeutic: Cladribine’s established efficacy combined with BioNxt’s innovative delivery system offers an advanced solution for MG treatment.

Next Steps for BNT23002

BioNxt is preparing to initiate clinical trials for BNT23002, following successful pre-clinical and pharmacokinetic studies. With plans for manufacturing scale-up alongside our research partners, we are dedicated to bringing this essential therapy to the MG community as soon as possible.

Learn More About BNT23002

For more information on BNT23002 and BioNxt’s mission to advance MG treatment, please contact us or follow our progress through regulatory milestones. Together, we are shaping a brighter future for those living with myasthenia gravis.